婴儿急性淋巴细胞白血病的治疗策略
本文以代表性病例区分KMT2A重排与KMT2A胚系婴儿ALL,并讨论分子诊断进展如何解析KMT2A胚系遗传学并指导治疗降阶。重点讨论KMT2A重排婴儿B细胞ALL中双特异性T细胞衔接抗体贝林妥欧单抗及自体/异基因嵌合抗原受体T细胞疗法的早期疗效与耐受性数据,并探讨改善风险分层、以新药替代当前强化疗中最具毒性环节。
要点
- KMT2A重排与KMT2A胚系婴儿ALL分子特征及治疗策略不同
- 贝林妥欧单抗及CAR-T在KMT2A重排婴儿B-ALL中显示早期疗效与耐受性
核心结论
- 分子诊断进展正在解析KMT2A胚系遗传学并指导治疗降阶。
- KMT2A重排婴儿B细胞ALL中,贝林妥欧单抗及自体/异基因CAR-T的早期疗效与耐受性数据有前景。
研究设计与样本
- 本文为How I treat类综述,以代表性病例说明KMT2A重排与KMT2A胚系婴儿ALL的差异。
主要发现
- KMT2A重排与KMT2A胚系婴儿ALL在分子特征和治疗策略上存在关键差异。
- 分子诊断进展有助于解析KMT2A胚系遗传学并指导治疗降阶。
- KMT2A重排婴儿B细胞ALL中,贝林妥欧单抗及自体/异基因CAR-T的早期疗效与耐受性数据有前景。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infant acute lymphoblastic leukemia (ALL) is an aggressive malignancy that has historically been associated with a very poor prognosis. Despite large cooperative international trials and incremental increases in intensity of therapy, there has been no significant improvement in outcome over the last 3 decades. Using representative cases, we highlight the key differences between KMT2A-rearranged and KMT2A-germ line infant ALL, and how advances in molecular diagnostics are unpicking KMT2A-germ line genetics and guiding treatment reduction. We focus on KM2TA-rearranged infant B-cell ALL for which the last few years have seen the emergence of novel therapies that both are more effective and less toxic than conventional chemotherapy. Of these, there is promising early data on the efficacy and tolerability of the bispecific T-cell engager monoclonal antibody, blinatumomab, as well as the use of autologous and allogeneic chimeric antigen receptor T-cell therapy. We discuss how we can improve risk stratification and incorporate these new agents to replace the most toxic elements of currently deployed intensive chemotherapy schedules with their associated unacceptable toxicity.
引用
- Bartram J, Ancliff P, Vora A, et al. How I treat infant acute lymphoblastic leukemia. Blood. 2025. PMID: 38905593. doi:10.1182/blood.2023023154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。